Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2024-02-15 00:00:00 ET · period of report 2024-02-13 · accession 0001714899-24-000059 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-02-15 | 2024-02-13+ | DNLI | Schuth Alexander O. | COFO, Sec | S - Sale | $17.62 | -22.8K | 187.3K | -11% | -$402.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-13 | S | D | 2,716 | $17.29 | 207,469 | D | — | — | (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.08 to $17.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 129,435 RSUs. |
| 2 | Common | Common Stock | 2024-02-14 | S | D | 20,128 | $17.66 | 187,341 | D | — | — | (F5) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.08 to $17.97 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 129,435 RSUs. |